LFCRHealthcare · Drug Manufacturers - Specialty & GenericThe 5 Wall Street analysts covering Lifecore Biomedical, Inc. hold a median 12-month price target of $6.25 — +37.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Lifecore Biomedical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (70): Smaller than most of the companies we track.
Quality (0): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LFCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +37.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 June 2026 | Barrington Research | Maintains | Outperform | $6.00 → $6.50 |
| 29 Apr 2026 | Barrington Research | Maintains | Outperform | — |
| 27 Mar 2026 | Barrington Research | Maintains | Outperform | — |
| 24 Mar 2026 | Barrington Research | Maintains | Outperform | — |
| 17 Mar 2026 | Barrington Research | Upgrade | Outperform | — |
| 4 Sept 2025 | Keybanc | Initiates | Sector Weight | — |
| 21 May 2025 | William Blair | Initiates | Outperform | — |
| 3 Jan 2025 | Stephens & Co. | Reiterates | Equal-Weight | — |
| 22 Nov 2024 | Craig-Hallum | Maintains | Buy | — |
| 5 Sept 2024 | Craig-Hallum | Initiates | Buy | — |
| 28 Aug 2024 | Barrington Research | Downgrade | Market Perform | — |
| 1 Sept 2023 | Barrington Research | Maintains | Outperform | — |
| 1 Sept 2023 | Stephens & Co. | Maintains | Equal-Weight | — |
| 2 June 2023 | Barrington Research | Maintains | Outperform | — |
| 24 May 2023 | Barrington Research | Maintains | Outperform | — |
| 21 Mar 2023 | Barrington Research | Maintains | Outperform | — |
| 20 Mar 2023 | Barrington Research | Maintains | Outperform | — |
| 20 Mar 2023 | Stephens & Co. | Downgrade | Equal-Weight | — |
| 17 Mar 2023 | Stephens & Co. | Reiterates | Overweight | — |
| 9 Dec 2022 | Baird | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LFCR appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 13% of US stocks
Cheaper than 64% of US stocks
Cheaper than 97% of US stocks
Cheaper than 6% of US stocks
Higher than 85% of US stocks
Higher than 33% of US stocks
Higher than 43% of US stocks
Higher than 59% of US stocks
Higher than 15% of US stocks
Higher than 99% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Lifecore Biomedical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of Lifecore Biomedical's second-quarter fiscal 2026 earnings call. The item is a record of the company's earnings call discussion.
Why it matters — Lifecore watchers use the transcript to review management's commentary on the company's latest quarterly results.
Lifecore Biomedical reported financial results for the second quarter and six months ended June 30, 2026. The company reaffirmed its 2026 guidance, announced multiple new business wins that add programs to its pipeline, and highlighted ongoing cost reduction and productivity enhancements, with a conference call held at 8:00am ET.
Why it matters — LFCR watchers would look for signs that the CDMO is holding its full-year outlook while expanding its pipeline through new client wins and ongoing operational improvement.
Lifecore Biomedical announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens.
Why it matters — A LFCR watcher would want to know the scheduled date for the company's quarterly earnings release to anticipate the upcoming financial performance update.
Lifecore Biomedical announced it has signed three new customer agreements: a technology transfer agreement for a regenerative medicine late-stage development program and two agreements supporting early-stage programs for a global medical technology company.
Why it matters — The agreements are additive to Lifecore's high-value pipeline and are expected to contribute to 2028 revenue, indicating continued business growth.
The 5 Wall Street analysts covering Lifecore Biomedical, Inc. have a median 12-month price target of $6.25, with estimates ranging from $5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Lifecore Biomedical, Inc., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lifecore Biomedical, Inc. 4 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Lifecore Biomedical, Inc. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (70 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +37.7% from the last close, and Ticker Nerd's factor model ranks Lifecore Biomedical, Inc. 4 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lifecore Biomedical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LFCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $9 over the next 12 months.
Lifecore Biomedical, Inc. returned -37.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Lifecore Biomedical Inc. is a prominent entity in the biotechnology sector, primarily engaged in the manufacture and development of high-quality biomedical products.
The most recent item we track (Seeking Alpha, 5 Aug 2026): "Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of Lifecore Biomedical's second-quarter fiscal 2026 earnings call. The item is a record of the company's earnings call discussion.
Lifecore Biomedical Inc. is a prominent entity in the biotechnology sector, primarily engaged in the manufacture and development of high-quality biomedical products. The company specializes in the production of hyaluronan and other polysaccharide-based products for medical applications. These biomaterials are crucial in various medical fields, including ophthalmology, orthopedics, and general surgery, thanks to their biocompatibility and multifunctional characteristics. Lifecore Biomedical Inc.'s expertise in manufacturing and formulation is underscored by its integration with the pharmaceutical and health industries, where its products are utilized in drug delivery systems and surgical applications. Established with a commitment to quality and innovation, the company plays a significant role in advancing medical technology and improving patient outcomes globally. Its presence in the market underscores the critical interface between leading-edge biotechnology and practical health applications, making it a key player in the advancement of medical treatments and technologies.
CEO Mr. Paul Josephs · 382 employees · United States · https://www.lifecore.com